PEGINTERFERON LAMBDA FOR THE TREATMENT OF CHRONIC HEPATITIS B (CHB): A PHASE 2B COMPARISON WITH PEGINTERFERON ALFA IN PATIENTS WITH HBeAg-POSITIVE DISEASE

被引：3
|
作者：
Chan, H. L. [1 ]
Ahn, S. H. [2 ]
Chang, T. -T. [3 ]
Peng, C. -Y. [4 ]
Wong, D. [5 ]
Coffin, C. S. [6 ]
Lim, S. G. [7 ]
Chen, P. -J. [8 ]
Janssen, H. L. [9 ,10 ]
Marcellin, P. [11 ]
Serfaty, L. [12 ]
Zeuzem, S. [13 ]
Cohen, D. [14 ]
Critelli, L. [14 ]
Xu, D. [14 ]
Cooney, E. [14 ]
机构：
[1] Chinese Univ Hong Kong, Div Gastroenterol & Hepatol, Shatin, Hong Kong, Peoples R China
[2] Yonsei Univ, Severance Hosp, Seoul 120749, South Korea
[3] Natl Chen Kung Univ Hosp, Tainan, Taiwan
[4] China Med Univ Hosp, Taichung, Taiwan
[5] Toronto Western Hosp, Univ Hlth Network, Toronto, ON M5T 2S8, Canada
[6] Univ Calgary, Div Gastroenterol & Hepatol, Liver Unit, Calgary, AB, Canada
[7] Natl Univ Singapore Hosp, Singapore 117548, Singapore
[8] Natl Taiwan Univ Hosp, Taipei, Taiwan
[9] Erasmus MC, Rotterdam, Netherlands
[10] Univ Hlth Network, Toronto, ON, Canada
[11] Hop Beaujon, Clichy, France
[12] Hop St Antoine, F-75571 Paris, France
[13] Goethe Univ Frankfurt, Med Ctr, D-60054 Frankfurt, Germany
[14] Bristol Myers Squibb Co, Res & Dev, Wallingford, CT 06492 USA
来源：
JOURNAL OF HEPATOLOGY | 2014年 / 60卷 / 01期
关键词：
D O I：
10.1016/S0168-8278(14)60117-3
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
O115
引用
收藏
页码：S48 / S48
页数：1
相关论文
共 50 条
  • [31] HBV DNA Suppression in HBeAg-Positive Chronic Hepatitis B Patients Treated With Peginterferon or Placebo
    Hansen, Bettina E.
    Rijckborst, Vincent
    ter Borg, Martijn J.
    Janssen, Harry L. A.
    JOURNAL OF MEDICAL VIROLOGY, 2011, 83 (11) : 1917 - 1923
  • [32] HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients
    Song Yang
    Huichun Xing
    Yuming Wang
    Jinlin Hou
    Duande Luo
    Qing Xie
    Qin Ning
    Hong Ren
    Huiguo Ding
    Jifang Sheng
    Lai Wei
    Shijun Chen
    Xiaoling Fan
    Wenxiang Huang
    Chen Pan
    Zhiliang Gao
    Jiming Zhang
    Boping Zhou
    Guofeng Chen
    Mobin Wan
    Hong Tang
    Guiqiang Wang
    Yuxiu Yang
    Dongping Xu
    Peiling Dong
    Qixin Wang
    Jue Wang
    Fernando A. Bognar
    Daozhen Xu
    Jun Cheng
    Virology Journal, 13
  • [33] Cytokine Profiles and Virological Marker Monitoring during 48 Weeks Peginterferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B
    LI Ming Hui
    SUN Fang Fang
    CHEN Feng Xin
    ZENG Zhan
    LIN Yan Jie
    BI Xiao Yue
    YANG Liu
    DENG Wen
    JIANG Ting Ting
    HUANG Rong Hai
    YI Wei
    XIE Yao
    Biomedical and Environmental Sciences, 2022, 35 (04) : 312 - 321
  • [34] Cytokine Profiles and Virological Marker Monitoring during 48 Weeks Peginterferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B
    Li Ming Hui
    Sun Fang Fang
    Chen Feng Xin
    Zeng Zhan
    Lin Yan Jie
    Bi Xiao Yue
    Yang Liu
    Deng Wen
    Jiang Ting Ting
    Huang Rong Hai
    Yi Wei
    Xie Yao
    BIOMEDICAL AND ENVIRONMENTAL SCIENCES, 2022, 35 (04) : 312 - 321
  • [35] Association between Genotype and the HBsAg Levels at HBeAg Loss in HBeAg-positive Chronic Hepatitis B Patients Treated with Entecavir or Peginterferon Alfa-2a
    Peng, Cheng-Yuan
    Lai, Hsueh-Chou
    Su, Wen-Pang
    Lin, Chia-Hsin
    Chuang, Po-Heng
    Chen, Sheng-Hung
    HEPATOLOGY, 2014, 60 : 1121A - 1121A
  • [36] Response to peginterferon alfa-2a (40KD) (PEGASYS) treatment in patients with bridging fibrosis in HBeAg-positive and HBeAg-negative chronic hepatitis B
    Cooksley, Graham
    Lau, George
    Marcellin, Patrick
    Piratvisuth, Teerha
    Lai, Ming-Yang
    Bonino, Ferruccio
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A32 - A32
  • [37] Peginterferon and Chinese herbs exert a combinatorial effect in HBeAg-positive chronic hepatitis B
    An, Yingfeng
    Gao, Shoucui
    Cheng, Daxin
    Wang, Xiaojing
    Bai, Liang
    Liu, Enqi
    Chu, Yonglie
    Zhao, Sihai
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2016, 10 (04): : 369 - 376
  • [38] ON-TREATMENT HBSAG AND HBEAG LEVELS AS POTENTIAL PREDICTORS OF DURABLE OFF-TREATMENT HBEAG SEROCONVERSION FOR HBEAG-POSITIVE CHB PATIENTS TREATED WITH PEGINTERFERON ALFA-2B NOT CONVENTIONAL INTERFERON ALFA-2B
    Ma, Hui
    Yang, Ruifeng
    Wei, Lai
    HEPATOLOGY, 2009, 50 (04) : 527A - 527A
  • [39] DURABILITY OF PEGINTERFERON ALFA-2B TREATMENT BEYOND 5 YEARS IN PATIENTS WITH HEPATITIS B E ANTIGEN (HBEAG) POSITIVE CHRONIC HEPATITIS B
    Wong, V. W. -S.
    Wong, G. L-H.
    Yan, K. K. -L.
    Chim, A. M. -L.
    Chan, H. -Y.
    Chan, H. L. -Y.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S399 - S399
  • [40] SERUM HBSAG LEVELS DURING PEGINTERFERON ALFA-2A TREATMENT IN HBEAG-POSITIVE CHRONIC HEPATITIS B: A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL
    Kim, Bo Hyun
    Kim, Won
    Song, Fun Young
    Park, Myoung Hee
    Yoon, Jung-Hwan
    Lee, Youn Jae
    Park, Sung Jae
    Jung, Eun Uk
    Kim, Donghee
    Kim, Yoon Jun
    Lee, Hyo-Suk
    HEPATOLOGY, 2010, 52 (04) : 514A - 514A
12345